Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
REVENUES        
Total revenues $ 460,100 $ 459,900 $ 847,200 $ 581,900
COST OF REVENUES        
Total cost of revenues 296,300 298,300 521,400 383,200
GROSS MARGIN 163,800 161,600 325,800 198,700
OPERATING EXPENSES        
Research 60,800 73,400 141,600 154,900
Product development 237,300 342,200 474,300 611,400
Sales and marketing 199,400 638,000 351,300 1,305,200
General and administrative 2,350,300 1,740,900 4,724,100 3,515,800
Total operating expenses 2,847,800 2,794,500 5,691,300 5,587,300
OPERATING LOSS (2,684,000) (2,632,900) (5,365,500) (5,388,600)
OTHER INCOME (EXPENSE):        
Interest expense, net (23,400) (24,800) (46,300) (38,500)
Total other income (expense) (23,400) (24,800) (46,300) (38,500)
LOSS BEFORE PROVISION FOR INCOME TAXES (2,707,400) (2,657,700) (5,411,800) (5,427,100)
Income taxes 2,300 1,900 2,300 1,900
NET LOSS (2,709,700) (2,659,600) (5,414,100) (5,429,000)
Net loss attributable to noncontrolling interest (451,100) (72,300) (778,000) (72,300)
Net Loss attributable to MYnd Analytics, Inc. $ (2,258,600) $ (2,587,300) $ (4,636,100) $ (5,356,700)
BASIC AND DILUTED LOSS PER SHARE: (in dollars per share) $ (0.27) $ (0.59) $ (0.59) $ (1.23)
WEIGHTED AVERAGE SHARES OUTSTANDING:        
Basic and Diluted (in shares) 8,399,443 4,362,564 7,964,021 4,347,745
Neurometric Services [Member]        
REVENUES        
Total revenues $ 44,800 $ 79,800 $ 124,000 $ 133,100
COST OF REVENUES        
Total cost of revenues 5,100 69,700 11,500 118,800
Telepsychiatry Services [Member]        
REVENUES        
Total revenues 415,300 380,100 723,200 448,800
COST OF REVENUES        
Total cost of revenues $ 291,200 $ 228,600 $ 509,900 $ 264,400